Tisagenlecleucel CAR-T receives additional FDA Approval for DLBCL

/0 Comments/in , /by

Tisagenlecleucel CAR-T receives additional FDA Approval for DLBCL

  • FDA approved tisagenlecleucel (KYMRIAH, Novartis Pharmaceuticals Corp.) a CD19-directed genetically modified autologous T-cell immunotherapy, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. More Information.

See all CAR-T therapies and indications

 

You might also like
ADDING-RIBOCICLIB-TO-FULVESTRANT-IMPROVES-THE-SURVIVAL-OF-ADVANCED-BREAST-CANCER-PATIENTS-MONALEESA-3CAR-T Axicabtagene ciloleucel FDA approved for relapsed or refractory large B-cell lymphoma
ADDING-RIBOCICLIB-TO-FULVESTRANT-IMPROVES-THE-SURVIVAL-OF-ADVANCED-BREAST-CANCER-PATIENTS-MONALEESA-3ESMO16 Breast Cancer: Palbociclib, Ribociclib and Abemaciclib Data
ASCO-2019-breast-cancer-TNBC-MBC-ABC-ASCO19-MONALEESA-7-TRINITI-1-FAKTION-TBCRC030-NeoSTOP-ETNA-GeparOLA-KRISTINE-PREDIX-CLEOPATRA-HERITAGE-SOPHIA-NALA-IMpassion-130ASCO 2019 Breast Cancer: The ASCO19 breast cancer track summarised
ADDING-RIBOCICLIB-TO-FULVESTRANT-IMPROVES-THE-SURVIVAL-OF-ADVANCED-BREAST-CANCER-PATIENTS-MONALEESA-3Alectinib FDA approved for ALK-positive metastatic NSCLC
ADDING-RIBOCICLIB-TO-FULVESTRANT-IMPROVES-THE-SURVIVAL-OF-ADVANCED-BREAST-CANCER-PATIENTS-MONALEESA-3FDA approved mogamulizumab for adult patients with relapsed or refractory CTCL
ADDING-RIBOCICLIB-TO-FULVESTRANT-IMPROVES-THE-SURVIVAL-OF-ADVANCED-BREAST-CANCER-PATIENTS-MONALEESA-3Atezolizumab FDA approved for PD-L1 positive unresectable triple-negative breast cancer
ADDING-RIBOCICLIB-TO-FULVESTRANT-IMPROVES-THE-SURVIVAL-OF-ADVANCED-BREAST-CANCER-PATIENTS-MONALEESA-3Ribociclib plus Fulvestrant Improves Survival in Advanced Breast Cancer
ADDING-RIBOCICLIB-TO-FULVESTRANT-IMPROVES-THE-SURVIVAL-OF-ADVANCED-BREAST-CANCER-PATIENTS-MONALEESA-3Plasma TMB predicts response to atezolizumab in NSCLC patients
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

Adjuvant dabrafenib plus trametinib FDA approved for BRAF V600E or V600K me...US FDA approved CAR-T cell and BiTE immunotherapy – Updated 2-May-201...